Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
9,917 results
- I-SCREENIndependent statistical analysis of Increasing Screening for Cancer Using EHR-Nudges: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06177795).
- I2PETHVIndependent statistical analysis of I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02323217).
- iAIM EDUIndependent statistical analysis of Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IASISIndependent statistical analysis of Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- iATTENDIndependent statistical analysis of The Improving ATTENDance to Cardiac Rehabilitation Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646760).
- Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05399641).
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IBSCIIndependent statistical analysis of The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibuprofen Extended-Release Dental Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Extended-Release Dental Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00707057).
- Ibuprofen With or Without Acetaminophen for Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen With or Without Acetaminophen for Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03554018).
- IC/BPSIndependent statistical analysis of Real-world Evidence Study on Cystistat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05544695).
- iCareIndependent statistical analysis of iCare Stress Management e-Training for Dementia Family Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01378195).
- ICEIndependent statistical analysis of Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00220740).
- ICIP-SAIndependent statistical analysis of Invasive Candidiasis in Saudi ICUs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01490684).
- iCLAS™ for Persistent Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of iCLAS™ for Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04061603).
- ICONIC-TOTALIndependent statistical analysis of A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet):…
- ICT-HCTIndependent statistical analysis of Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ictal and Interictal Inflammatory Markers in Migraine: Complete Statistical AnalysisIndependent statistical analysis of Ictal and Interictal Inflammatory Markers in Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138150).
- Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: Complete Statistical AnalysisIndependent statistical analysis of Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ID11-56Independent statistical analysis of An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- iDCLIndependent statistical analysis of The International Diabetes Closed Loop (iDCL) Trial: Protocol 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02985866).
- IDEAIndependent statistical analysis of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04425863).
- IDEALEIndependent statistical analysis of Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study):…
- Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Identifying and Treating Depression in Hemodialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Identifying and Treating Depression in Hemodialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03390933).
- IDENTITY-2Independent statistical analysis of Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: Complete Statistical AnalysisIndependent statistical analysis of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02854059).
- iDIETIndependent statistical analysis of The Immune Directed Individualized Elimination Therapy (iDIET) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05543512).
- IDMPCIndependent statistical analysis of Improving Depression Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05050227).
- IETPPEIndependent statistical analysis of Investigations of Ear Tip Performance, Perceptions, and Experiences: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05725824).
- IF-AMDIndependent statistical analysis of Improving Function in Age-Related Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00572039).
- IFUMIndependent statistical analysis of Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IGF-1 and Bone Loss in Women With Anorexia Nervosa: Complete Statistical AnalysisIndependent statistical analysis of IGF-1 and Bone Loss in Women With Anorexia Nervosa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01406444).
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s): Complete Statistical AnalysisIndependent statistical analysis of iGlarLixi vs IDegAsp in Chinese Participants After OAD(s): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05413369).
- IGNAZIndependent statistical analysis of Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IHAIndependent statistical analysis of Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IKEEGIndependent statistical analysis of EEG Changes With Guided Online Meditation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03459690).
- IKEMAIndependent statistical analysis of Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: Complete Statistical AnalysisIndependent statistical analysis of IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524342).
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: Complete Statistical AnalysisIndependent statistical analysis of IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IL-17 Neutrophils in CF Lung Inflammation: Complete Statistical AnalysisIndependent statistical analysis of IL-17 Neutrophils in CF Lung Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02025829).
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: Complete Statistical AnalysisIndependent statistical analysis of IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ILA115938Independent statistical analysis of Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Illness Management and Recovery for Veterans With Severe Mental Illness: Complete Statistical AnalysisIndependent statistical analysis of Illness Management and Recovery for Veterans With Severe Mental Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515671).
- ILMARI2Independent statistical analysis of Impact of Adding a Limitation Section in Abstract of Systematic Review: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability: Complete Statistical AnalysisIndependent statistical analysis of Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…